Evidence map›Paper›PMID 32296708›Full record

ArticleFrontiers in medicine2020

Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Not Due to Anti-mitochondrial Antibodies.

Isabell Nilsson, Jeremy Palmer, Eirini Apostolou, Carl-Gerhard Gottfries, Muhammad Rizwan, Charlotte Dahle, Anders Rosén

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04592354 (Anhydrous Enol-Oxaloacetate), which is not on this map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04592354 naunknown statusnot on this map

Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors

TypeinterventionalSponsorTerra Biological LLCRan2020 to 2021Enrolled40ConditionsTreatment of Fatigue After Resolution of COVID-19 InfectionArmsOxaloacetate Medical Food/Dietary Supplement
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Recent research in myalgic encephalomyelitis/chronic fatigue syndrome: an evidence map.Health technology assessment (Winchester, England) · 2025
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Isabell NilssonDivision of Cell Biology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Jeremy PalmerThe Medical School, The University Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.
Eirini ApostolouDivision of Cell Biology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Carl-Gerhard GottfriesThe Gottfries Clinic AB, Mölndal, Sweden.
Muhammad RizwanDivision of Cell Biology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Charlotte DahleDivision of Cell Biology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Anders RosénDivision of Cell Biology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Linköping University · SENewcastle University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic profiling studies have recently indicated dysfunctional mitochondria in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This includes an impaired function of pyruvate dehydrogenase complex (PDC), possibly driven by serum factor(s), which leads to inadequate adenosine triphosphate generation and excessive lactate accumulation. A reminiscent energy blockade is likely to occur in primary biliary cholangitis (PBC), caused by anti-PDC autoantibodies, as recently proposed. PBC is associated with fatigue and post-exertional malaise, also signifying ME/CFS. We herein have investigated whether ME/CFS patients have autoreactive antibodies that could interfere with mitochondrial function. We found that only 1 of 161 examined ME/CFS patients was positive for anti-PDC, while all PBC patients (15/15) presented significant IgM, IgG, and IgA anti-PDC reactivity, as previously shown. None of fibromyalgia patients (0/14), multiple sclerosis patients (0/29), and healthy blood donors (0/44) controls showed reactivities. Anti-mitochondrial autoantibodies (inner and outer membrane) were negative in ME/CFS cohort. Anti-cardiolipin antibody levels in patients did not differ significantly from healthy blood donors. In conclusion, the impaired mitochondrial/metabolic dysfunction, observed in ME/CFS, cannot be explained by presence of circulating autoantibodies against the tested mitochondrial epitopes.

Indexed as

AMAanti-mitochondrial autoantibodiesanti-pyruvate dehydrogenase complex antibodiesmyalgic encephalomyelitis/chronic fatigue syndromePDC

Identifiers

PMID32296708
PMCPMC7136523
OpenAlexW3014890439

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.